The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19

NCT04798716 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19
Novel Coronavirus Pneumonia
Acute Respiratory Distress Syndrome

Interventions

DRUG: MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)
DRUG: MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)
DRUG: MSC-exosomes delivered intravenously every other day (8:8:8)

Sponsor

AVEM HealthCare